tiprankstipranks
Trending News
More News >
Carisma Therapeutics, Inc. (CARM)
:CARM
Advertisement

Carisma Therapeutics (CARM) AI Stock Analysis

Compare
1,648 Followers

Top Page

CARM

Carisma Therapeutics

(NASDAQ:CARM)

Rating:42Neutral
Price Target:
$0.50
▲(47.06%Upside)
Carisma Therapeutics faces severe financial difficulties, with negative equity and ongoing losses. Technical indicators suggest a bearish outlook, while valuation metrics reflect the company's struggling position. The recent corporate event highlights compliance issues but also shows attempts to address these challenges.
Positive Factors
Clinical Trials
The mesothelin targeted autologous CAR monocyte program is expected to show evidence of clinical responses and clean safety, which should de-risk and validate the monocyte platform.
Strategic Partnerships
Carisma will focus on developing off-the-shelf products using its in vivo macrophage engineering platform, including those under the Moderna partnership.
Negative Factors
Program Discontinuation
Carisma Therapeutics announced that it would be discontinuing development of its lead program, CT-0525.
Workforce Reduction
As part of the strategic restructuring, Carisma will reduce its workforce by 34%.

Carisma Therapeutics (CARM) vs. SPDR S&P 500 ETF (SPY)

Carisma Therapeutics Business Overview & Revenue Model

Company DescriptionCarisma Therapeutics (CARM) is a biotechnology company focused on developing innovative immunotherapies for the treatment of cancer and other serious diseases. The company specializes in the engineering of macrophages, a type of white blood cell, to harness the power of the immune system to target and eliminate cancer cells. Carisma's proprietary technology platform aims to create a new class of cell therapies that can overcome the limitations of current cancer treatments.
How the Company Makes MoneyCarisma Therapeutics makes money primarily through the development and commercialization of its proprietary immunotherapy products. The company generates revenue through partnerships and collaborations with other biotech and pharmaceutical companies, which may include milestone payments, royalties, and licensing fees related to its technology and drug candidates. Additionally, Carisma may receive funding from grants and research contracts to support its ongoing research and development activities. The company's earnings are significantly influenced by its ability to advance its product pipeline through clinical trials and achieve regulatory approvals, as well as its success in securing strategic alliances and partnerships.

Carisma Therapeutics Financial Statement Overview

Summary
Carisma Therapeutics is facing significant financial challenges across all verticals. The income statement shows persistent losses, the balance sheet reflects financial instability with negative equity, and cash flow statements indicate liquidity issues. The company needs to address operational inefficiencies and improve its financial health to ensure long-term sustainability.
Income Statement
35
Negative
Carisma Therapeutics has shown a declining revenue trend with a significant drop in profitability. The TTM (Trailing-Twelve-Months) gross profit margin is relatively high at 95.38%, but the company is struggling with negative EBIT and net profit margins, indicating operational inefficiencies and high costs relative to revenue. The revenue growth rate is modest at 1.69% from the previous year, but the persistent net losses are concerning.
Balance Sheet
25
Negative
The balance sheet reveals a challenging financial position with negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio is not applicable due to negative equity, and the equity ratio is also negative, reflecting financial instability. The company's high liabilities and negative equity pose significant risks.
Cash Flow
30
Negative
Carisma Therapeutics has negative operating and free cash flows, indicating cash outflows exceed inflows. The operating cash flow to net income ratio is 0.94, suggesting cash flow issues. Although there is a slight improvement in free cash flow growth rate, the overall cash flow position remains weak, raising concerns about liquidity.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue19.63M14.92M9.83M26.54M11.24M
Gross Profit16.28M-59.21M3.74M26.46M11.24M
EBITDA-58.83M-85.89M-51.99M-40.11M-27.93M
Net Income-60.48M-86.88M-61.23M-40.78M-28.35M
Balance Sheet
Total Assets30.46M89.55M72.15M35.45M58.46M
Cash, Cash Equivalents and Short-Term Investments17.91M77.61M52.00M28.55M51.79M
Total Debt2.48M3.12M40.16M2.63M3.44M
Total Liabilities58.37M63.02M101.28M9.43M8.31M
Stockholders Equity-27.91M26.53M-49.26M11.63M35.76M
Cash Flow
Free Cash Flow-60.04M-82.31M-12.23M-39.20M-27.45M
Operating Cash Flow-59.92M-81.18M-7.57M-37.33M-27.01M
Investing Cash Flow-123.00K72.41M-32.56M-1.87M-440.00K
Financing Cash Flow344.00K62.18M35.77M15.96M72.26M

Carisma Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.34
Price Trends
50DMA
0.36
Negative
100DMA
0.32
Positive
200DMA
0.49
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
42.09
Neutral
STOCH
15.56
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CARM, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.40, below the 50-day MA of 0.36, and below the 200-day MA of 0.49, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.09 is Neutral, neither overbought nor oversold. The STOCH value of 15.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CARM.

Carisma Therapeutics Risk Analysis

Carisma Therapeutics disclosed 82 risk factors in its most recent earnings report. Carisma Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Carisma Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
$8.92M4.67-41.13%
52
Neutral
kr5.61B10.15-63.86%2.10%27.11%26.73%
49
Neutral
$9.21M-451.34%-57.84%
42
Neutral
$15.27M-362.79%32.45%39.31%
39
Underperform
$12.55M-285.79%23.65%
34
Underperform
$8.16M-126.03%-100.00%-27.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CARM
Carisma Therapeutics
0.34
-0.73
-68.22%
KPRX
Kiora Pharmaceuticals
2.74
-1.89
-40.82%
DWTX
Dogwood Therapeutics
4.80
-0.48
-9.09%
ACXP
Acurx Pharmaceuticals
0.38
-1.78
-82.41%
TSBX
Turnstone Biologics Corp.
0.35
-2.03
-85.29%

Carisma Therapeutics Corporate Events

Delistings and Listing ChangesShareholder MeetingsStock Split
Carisma Therapeutics Transfers Listing to Nasdaq Capital Market
Negative
Jul 15, 2025

On January 6, 2025, Carisma Therapeutics was notified by Nasdaq that it failed to meet the minimum bid price requirement for continued listing on the Nasdaq Global Market. Despite being given a grace period until July 7, 2025, the company did not regain compliance, leading to a potential delisting threat. Following a hearing, Nasdaq allowed Carisma to transfer its listing to the Nasdaq Capital Market effective June 12, 2025, with a deadline to meet all listing criteria by October 7, 2025. To address this, Carisma scheduled a special stockholders’ meeting for August 5, 2025, to approve a reverse stock split aimed at increasing its share price and maintaining its listing status.

The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.

M&A Transactions
Carisma Therapeutics Announces Merger with OrthoCellix
Neutral
Jun 23, 2025

On June 22, 2025, Carisma Therapeutics announced a merger agreement with OrthoCellix, a subsidiary of Ocugen, to create a Nasdaq-listed company focused on regenerative cell therapies for orthopedic diseases. The merger will result in OrthoCellix owning approximately 90% of the combined entity, with plans to initiate a Phase 3 clinical trial for its NeoCart® technology by the end of 2025, potentially impacting the market for cartilage repair solutions.

The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.

Delistings and Listing ChangesRegulatory Filings and Compliance
Carisma Therapeutics Secures Nasdaq Listing Approval
Neutral
Jun 12, 2025

On June 10, 2025, Carisma Therapeutics received approval from a Nasdaq Hearings Panel to continue its listing on Nasdaq, with the listing being transferred to the Nasdaq Capital Market effective June 12, 2025. Despite previous non-compliance with Nasdaq’s listing rules, the company has been granted an extension until October 7, 2025, to meet specific conditions, including maintaining a minimum bid price and completing a strategic transaction, to ensure continued listing.

The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 30, 2025